期刊文献+

肝癌患者外周血γδ T细胞比例及功能变化研究 被引量:2

Changes in proportion and function of peripheral bloodγδT cells in patients with hepatocellular carcinoma
原文传递
导出
摘要 目的观察肝癌患者外周血γδT细胞及其2个不同亚型,即Vδ1和Vδ2 T细胞比例和功能的变化,探讨γδT细胞及其2个不同亚型,即Vδ1和Vδ2 T细胞在肝癌发生发展中的作用。方法分析2019年1月5日—11月31日在焦作市第三人民医院确诊并接受手术治疗的20例肝癌患者外周血,同期收集20名健康体检者(对照组)外周血作为对照。通过流式细胞术分析对照组和肝癌组外周血中γδT细胞、Vδ1 T细胞和Vδ2 T细胞的比例;通过抗体扩增能力检测对照组外周血和肝癌组外周血γδT细胞、Vδ1 T细胞和Vδ2 T细胞的增殖能力;通过流式细胞术分析对照组和肝癌组外周血扩增Vδ1 T细胞表面Foxp2表达情况;通过增殖实验检测对照组和肝癌组外周血扩增Vδ1 T细胞的免疫抑制能力;通过流式细胞术分析对照组和肝癌组外周血扩增Vδ2 T细胞分泌TNF-α情况;通过杀伤实验检测对照组和肝癌组外周血Vδ2 T细胞对肝癌细胞系Hep G2的杀伤能力。结果肝癌患者外周血中γδT细胞和Vδ2 T细胞比例显著降低,而Vδ1 T细胞比例显著升高(P<0.01)。肝癌组外周血的Vδ1 T细胞表现出更强的增殖能力(P<0.01),而Vδ2 T细胞的增殖能力有所降低(P<0.01)。肝癌组外周血扩增Vδ1 T细胞表达更高水平的Foxp3,且表现出更强的抑制功能(P<0.01)。肝癌组外周血扩增Vδ2 T细胞TNF-α分泌能力和对肝癌细胞的杀伤能力均显著降低(P<0.01)。结论肝癌患者外周血中Vδ1和Vδ2 T细胞比例失衡和功能的改变可能与肝癌的免疫逃逸相关。
作者 焦月琴 赵云峰 刘小壮 闫彩红 JIAO Yue-qin;ZHAO Yun-feng;LIU Xiao-zhuang;YAN Cai-hong
出处 《实用预防医学》 CAS 2020年第7期884-888,共5页 Practical Preventive Medicine
  • 相关文献

参考文献2

二级参考文献37

  • 1Peng L, Shu S Krauss JC. Treatment of subcutaneous tumor with adoptively transferred T cells. Cell Immuno11997; 178: 24-32.
  • 2Rosenberg SA, Spiess P, Lafreniere R. A new approach tothe adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 233: 1318-1321.
  • 3Plautz GE, Bukowski RM, Novick AC, Klein EA, Kursh ED, Olencki TE et al T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology1999; 54: 617-623; discussion 623-614.
  • 4Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL etalAdoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001; 24: 363-373.
  • 5Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3: 666-675.
  • 6Clay TM, Custer MC, Sachs J, Hwu P, Rosenberg SA, Nishimura MI. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti- tumor reactivity. J Immuno11999; 163: 507-513.
  • 7Morgan RA, Dudley ME, Yu YY, Zheng Z, Robbins PF, Theoret MR etaL High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. J Immuno12003; 171: 3287-3295.
  • 8Hughes MS, Yu YY, Dudley M E, Zheng Z, Robbins PF, Li Y etal Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum Gene TheY2005; 16: 457-472.
  • 9Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball Jet al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immuno12001; 2: 962-970.
  • 10Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM etal. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.

共引文献22

同被引文献13

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部